Forty-seven adult patients with CAPS with mutations in NLRP3 (CIAS1) gene and pathognomonic symptoms. Weekly subcutaneous injections of rilonacept (160 mg). This evidence concerns the gene NLRP3 and cryopyrin-associated periodic syndrome.